High level of interleukin-10 in serum predicts poor prognosis in multiple myeloma (Q36750576)

16 August 2017

High level of interleukin-10 in serum predicts poor prognosis in multiple myeloma (English)

1 reference

16 August 2017

Hua Wang

1

1 reference

16 August 2017

Liang Wang

2

1 reference

16 August 2017

Pei-Dong Chi

3

1 reference

16 August 2017

Wei-da Wang

4

1 reference

16 August 2017

Xiao-Qin Chen

5

1 reference

16 August 2017

Qi-Rong Geng

6

1 reference

16 August 2017

Zhong-Jun Xia

7

1 reference

16 August 2017

Yue Lu

8

1 reference

16 August 2017

language of work or name

English

0 references

publication date

4 February 2016

1 reference

British Journal of Cancer

16 August 2017

1 reference

16 August 2017

114

1 reference

16 August 2017

4

1 reference

16 August 2017

463-468

1 reference

Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International

16 August 2017

start time

1 February 2016

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

exact match

https://scigraph.springernature.com/pub.10.1038/bjc.2016.11

0 references

cites work

IL10 and PD-1 Cooperate to Limit the Activity of Tumor-Specific CD8+ T Cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4815778

TPL2 kinase regulates the inflammatory milieu of the myeloma niche

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4815778

Functionally suppressive CD8 T regulatory cells are increased in patients with multiple myeloma: a cause for immune impairment.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4815778

Bone marrow microenvironment in multiple myeloma progression.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4815778

Role of interleukin 16 in multiple myeloma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4815778

Immunotherapy using dendritic cells against multiple myeloma: how to improve?

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4815778

Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant JAK2 activation

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4815778

Tolerance induced by apoptotic antigen-coupled leukocytes is induced by PD-L1+ and IL-10-producing splenic macrophages and maintained by T regulatory cells.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4815778

A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4815778

The role of complete response in multiple myeloma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4815778

The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4815778

Improved survival in multiple myeloma and the impact of novel therapies

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4815778

International uniform response criteria for multiple myeloma.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4815778

Interleukin-10 and the interleukin-10 receptor

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4815778

Interleukin-10 and cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4815778

Expression levels of IL-27 and IL-17 in multiple myeloma patients: a higher ratio of IL-27:IL-17 in bone marrow was associated with a superior progression-free survival

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4815778

Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4815778

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised p

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4815778

Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4815778

Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4815778

Serum levels of interleukin-15 and interleukin-10 and their correlation with proliferating cell nuclear antigen in multiple myeloma.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4815778

Possible contribution of circulating interleukin-10 (IL-10) to anti-tumor immunity and prognosis in patients with unresectable hepatocellular carcinoma

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4815778

Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myeloma.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4815778

Interleukin 10 abolishes the growth inhibitory effects of all-trans retinoic acid on human myeloma cells

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4815778

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4815778

Biological properties of interleukin 10

20 October 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FBJC.2016.11

Serum level of interleukin-16 in multiple myeloma patients and its relationship to disease activity

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FBJC.2016.11

Elevated Serum Levels of IL-10 are Associated with Inferior Progression-Free Survival in Patients with Hodgkin's Disease Treated with Radiotherapy

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FBJC.2016.11

Interleukin-10 is a growth factor for human myeloma cells by induction of an oncostatin M autocrine loop

21 January 2018

1 reference

12 December 2020

Interleukin-10 Induces Both Plasma Cell Proliferation and Angiogenesis in Multiple Myeloma

1 reference

12 December 2020

1 reference

12 December 2020

Thyroid cancer resistance to chemotherapeutic drugs via autocrine production of interleukin-4 and interleukin-10

1 reference

12 December 2020

Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials

1 reference

12 December 2020

Interleukin-10 is a proliferation factor but not a differentiation factor for human myeloma cells

1 reference

12 December 2020

Identifiers

DOI

10.1038/BJC.2016.11

1 reference

16 August 2017

1 reference

16 August 2017

1 reference